In the Know: Key Abstracts from the American Society of Hematology 2021 Annual Meeting in Acute Lymphoblastic Leukemia***Poster 1 Post-assessment*** Survey

In order to receive credit for this activity, you must read the front matter, view the activity, achieve a passing score of at least 75% on this post-survey, as well as complete the evaluation and application for credit form. Certificates of credit will be emailed to participants who have successfully met these requirements.

There is no fee to participate in this activity.

2.What is your area of specialty?

Hematology

Oncology

Other (please specify)

3.How many years have you been in practice?

<1

1-10

11-20

>21

4.Please select the option that best describes your practice setting:

5.Of the patients you will see in the next month, about how many will benefit from the information you learned today?

6.After participating in this activity, how confident are you in the management of patients with ALL in your practice?

7.Which of the following best describes how asparaginase erwinia chrysanthemi (recombinant)-rywn (ERW-rywn) asparaginase erwinia chrysanthemi (ERW) are similar?(Required.)

Neither product is prone to drug shortages

Neither product is approved for use in pediatric patients

Both are manufactured via recombinant DNA technology

Both can be administered intramuscularly

8.SP is a 10-year-old male who developed a grade 3 hypersensitivity reaction after his 3rd dose of pegaspargase on COG protocol AALL0232 for high-risk ALL. The pharmacy is unable to obtain ERW due to drug shortage.

Which of the following is most appropriate for SP?(Required.)

Administer ERW-rywn

Administer calaspargase pegol

Provide premedications and continue pegaspargase

Discontinue asparaginase

9.Which of the following was observed in serum asparaginase activity in the phase 2/3 clinical trial that led to FDA-approval of asparaginase erwinia chrysanthemi (recombinant)-rywn (ERW-rywn) in cohort 1a (25 mg/m2 IM on Monday, Wednesday, Friday)?(Required.)

SAA levels > 0.4 IU/mL at 48 hours in more than 60% of patients

SAA levels > 0.1 IU/mL at 48 hours in more than 90% of patients

SAA levels > 0.4 IU/mL at 72 hours in more than 60% of patients

SAA levels > 0.1 IU/mL at 72 hours in more than 90% of patients

Evaluation Form
In order to receive a CME/CE certificate for your participation in this activity, please complete this form in its entirety.

10.How committed are you to making changes in your practice based on your participation in this activity?(Required.)

If not committed or do not plan to make changes, please indicate reason

11.Which of the following best describes the impact of this activity on your performance?(Required.)

I gained new strategies/skills/information I can apply to my area of practice

I need more information before I can change my practice

My practice is already consistent with the information presented

This activity will not change my practice

12.Which new strategies/skills/information will you apply to your area of practice?

Recognize the role of asparaginase, pegaspargase, and alaspargase pegol in the front-line treatment of ALL

Utilize therapeutic drug monitoring to help discern between different treatment reactions

Recall management strategies for asparaginase toxicity

Determine when rechallenge with asparaginase is possible

13.What barriers do you see to making changes in your practice?

Lack of knowledge regarding evidence-based strategies

Lack of convincing evidence to warrant change

Lack of time/resources to consider change

Insurance, reimbursement or legal issues

Conflicting guidelines or evidence

Patient compliance and/or patient resource barriers

Other (please specify)

17.If you indicated that you perceived commercial bias or influence, please describe:

18.As a result of your participation in this activity, what is the one change you are most likely to implement in your practice?

19.Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities for this or related ALL:

20.Please let us know who you are so we can connect your responses to your pre-test & application to claim CME credit.

First & Last Name

Degree/Credentials

ZIP/Postal Code

Country

Email Address

21.I certify that I have participated in the continuing education activity entitled, “In the Know: Key Abstracts from the American Society of Hematology 2021 Annual Meeting in Acute Lymphoblastic Leukemia" and claim 0.5 AMA PRA Category 1 Credit^TM.

Yes

No